InsiderSignal.AI

InsiderSignal.ai

VIR - Vir Biotechnology, Inc.

Insider Sale by De Backer Marianne (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, De Backer Marianne, serving as Pres, CEO at Vir Biotechnology, Inc. (VIR), sold 72,559 shares at $9.16 per share, for a total transaction value of $664,350.00. Following this transaction, De Backer Marianne now holds 1,001,263 shares of VIR.

This sale represents a 7.00% decrease in De Backer Marianne's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 7, 2026, 1 day after the trade was made.

Vir Biotechnology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

De Backer Marianne

Pres, CEO

Marianne De Backer is the Chief Executive Officer and Director of Vir Biotechnology, Inc., a position she has held since April 2023[[5]](https://www.fiercebiotechweek.com/event/contact/marianne-backer). She brings over three decades of executive management experience in the biopharmaceutical industry, having previously served as Executive Vice President and Head of Pharmaceuticals Strategy, Business Development and Licensing at Bayer AG, where she was also a member of the Executive Committee of Bayer Pharmaceuticals[[6]](https://www.biocom.org/people/marianne-de-backer/)[[8]](https://www.fiercebiotech.com/biotech/how-vir-found-one-ceo-marianne-de-backer). Prior to her tenure at Bayer, Dr. De Backer spent more than 20 years at Johnson & Johnson in roles ranging from scientist to corporate development and international commercial leadership[[9]](https://investors.vir.bio/news/news-details/2023/Vir-Biotechnology-Announces-Retirement-of-CEO-George-Scangos-Ph.D.-Appoints-Marianne-De-Backer-MSc-Ph.D.-MBA-as-Successor-01-25-2023/default.aspx). Under Dr. De Backer's leadership since joining Vir, the company has undergone strategic transformation, sharpening its focus on infectious diseases while advancing innovation in oncology[[5]](https://www.fiercebiotechweek.com/event/contact/marianne-backer)[[7]](https://www.biotechtv.com/post/biotech-ceo-sisterhood-marianne-de-backer). She has been directly accountable for more than 200 strategic alliances in healthcare, many of which have resulted in newly approved medicines[[6]](https://www.biocom.org/people/marianne-de-backer/). Dr. De Backer holds a Master's degree in Molecular Biology from Vrije Universiteit Brussel, a Master's degree in Engineering and Biochemistry from Ghent University in Belgium, and a Ph.D. in Biotechnology from Ghent University, along with an MBA from Erasmus University, Rotterdam[[9]](https://investors.vir.bio/news/news-details/2023/Vir-Biotechnology-Announces-Retirement-of-CEO-George-Scangos-Ph.D.-Appoints-Marianne-De-Backer-MSc-Ph.D.-MBA-as-Successor-01-25-2023/default.aspx). She has been recognized as one of the "100 Most Influential Women" in German business (2022), a "Fiercest Woman in Life Sciences" by Fierce Pharma (2020), and one of the "Most Influential Women in Bay Area Business" (2020)[[9]](https://investors.vir.bio/news/news-details/2023/Vir-Biotechnology-Announces-Retirement-of-CEO-George-Scangos-Ph.D.-Appoints-Marianne-De-Backer-MSc-Ph.D.-MBA-as-Successor-01-25-2023/default.aspx).

View full insider profile →

Trade Price

$9.16

Quantity

72,559

Total Value

$664,350.00

Shares Owned

1,001,263

Trade Date

Monday, April 6, 2026

3 days ago

SEC Filing Date

Tuesday, April 7, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Vir Biotechnology, Inc.

Company Overview

No company information available
View news mentioning VIR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5446357

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime